

**10/586958**  
**IAP11 Rec'd PCT/PTO 26 JUL 2006**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Pierre MARTIN et al.

Title: SYNTHESIS METHODS AND INTERMEDIATES FOR THE  
MANUFACTURE OF RIZATRIPTAN

Appl. No.: Not Assigned

Filing Date: July 26, 2006

Examiner: Not Assigned

Art Unit: Not Assigned

Atty Docket No: LNK-018

**MAIL STOP AMENDMENT**  
Honorable Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. Accordingly, no certification or fee is required.

The documents listed on the Form PTO-1449 attached hereto were cited during prosecution of the international phase of the instant application (PCT/EP05/000793). Copies of the foreign patent references and non-patent literature cited are enclosed herewith. However, in

IAP11 Rec'd PCT/PTO 26 JUL 2006

accordance with the revised procedures under 37 CFR 1.98(a)(2)(i), copies of the cited U.S. patent references have not been provided.

In accordance with 37 C.F.R. §§ 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item, and Applicant reserves the right to prove that the date of publication is in fact different.

The Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 50-2101.

Respectfully submitted,

Date: 07/26/06

By: 

SMITH PATENT CONSULTING, LLC  
P.O. Box 2726  
Alexandria, VA 22301

Name: Chalin A. Smith  
Title: Attorney for Applicant  
Registration No. 41,569

Tel: 703-549-7691  
Fax: 703-549-7692

**CUSTOMER NUMBER 31,496**

SHEET 1 OF 1

<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)</b>				ATTY. DOCKET NO. <b>LNK-018</b>		SERIAL NO. <b>Not Assigned (National Phase of PCT/EP05/000793)</b>	
				APPLICANT <b>Pierre MARTIN et al.</b>			
				NATIONAL PHASE FILING DATE <b>July 26, 2006</b>		GROUP <b>Not Assigned</b>	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	4,556,717	12-1985	Wetter et al.	--	--		
	5,510,359	04-1996	Castro Pineiro et al.	--	--		
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY/APPLICANT	CLASS	SUBCLASS	Translation Yes      No	
(A)	0 497 512 A2	08-1992	Merck Sharp & Dohme Ltd (EPO)	--	--		
(B)	WO 95/32197	11-1995	Merck & Co., Inc. (WIPO)	--	--		
(C)	WO 04/056769 A2	07-2004	Ciba Specialty Chemicals Holding Inc. (WIPO)	--	--		
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
(D)	Written Opinion of the International Searching Authority issued in PCT/EP05/000793(2005)						

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.